Baseline characteristics
| Variable . | All patients N = 547 (%) . | M-protein n = 173 . | No M-protein n = 374 . | P value . |
|---|---|---|---|---|
| Median age, range (y) | 63 (19-98) | 65 (35-98) | 62 (19-93) | < .01 |
| Sex, n (%) | .05 | |||
| Males | 280 (51) | 99 (57) | 181 (48) | |
| Females | 267 (49) | 74 (43) | 193 (52) | |
| BMI < 30 kg/m2, n (%) | 357 (69) | 116 (72) | 241 (67) | .26 |
| MZL subtype, n (%) | .02 | |||
| EMZL | 319 (58) | 86 (50) | 233 (62) | |
| NMZL | 121 (22) | 49 (28) | 72 (19) | |
| SMZL | 107 (20) | 38 (22) | 69 (18) | |
| ECOG PS, n (%) | .01 | |||
| 0 | 291 (57) | 74 (47) | 217 (62) | |
| 1 | 185 (36) | 67 (43) | 118 (33) | |
| ≥2 | 34 (7) | 16 (10) | 18 (5) | |
| Stage, n (%) | < .01 | |||
| 1-2 | 215 (40) | 46 (27) | 169 (46) | |
| 3-4 | 321 (60) | 125 (73) | 196 (54) | |
| B symptoms, n (%) | 110 (20) | 41 (25) | 69 (19) | .10 |
| LDH > ULN, n (%) | 137 (27) | 40 (25) | 97 (27) | .66 |
| Albumin < ULN, n (%) | 91 (17) | 39 (24) | 52 (14) | < .01 |
| BM involvement, n (%) | 185 (47) | 82 (65) | 103 (38) | .001 |
| First-line treatment, n (%) | < .01 | |||
| R | 244 (45) | 72 (42) | 172 (46) | |
| BR | 110 (20) | 51 (29) | 59 (16) | |
| R-CHOP | 25 (5) | 6 (3) | 19 (5) | |
| R-CVP | 16 (3) | 8 (5) | 8 (2) | |
| Other systemic therapy | 20 (4) | 8 (5) | 12 (3) | |
| XRT | 19 (16) | 21 (12) | 70 (19) | |
| Surgery | 41 (7) | 7 (4) | 34 (9) | |
| Median follow-up (y) | 4.4 | 4.6 | 4.3 |
| Variable . | All patients N = 547 (%) . | M-protein n = 173 . | No M-protein n = 374 . | P value . |
|---|---|---|---|---|
| Median age, range (y) | 63 (19-98) | 65 (35-98) | 62 (19-93) | < .01 |
| Sex, n (%) | .05 | |||
| Males | 280 (51) | 99 (57) | 181 (48) | |
| Females | 267 (49) | 74 (43) | 193 (52) | |
| BMI < 30 kg/m2, n (%) | 357 (69) | 116 (72) | 241 (67) | .26 |
| MZL subtype, n (%) | .02 | |||
| EMZL | 319 (58) | 86 (50) | 233 (62) | |
| NMZL | 121 (22) | 49 (28) | 72 (19) | |
| SMZL | 107 (20) | 38 (22) | 69 (18) | |
| ECOG PS, n (%) | .01 | |||
| 0 | 291 (57) | 74 (47) | 217 (62) | |
| 1 | 185 (36) | 67 (43) | 118 (33) | |
| ≥2 | 34 (7) | 16 (10) | 18 (5) | |
| Stage, n (%) | < .01 | |||
| 1-2 | 215 (40) | 46 (27) | 169 (46) | |
| 3-4 | 321 (60) | 125 (73) | 196 (54) | |
| B symptoms, n (%) | 110 (20) | 41 (25) | 69 (19) | .10 |
| LDH > ULN, n (%) | 137 (27) | 40 (25) | 97 (27) | .66 |
| Albumin < ULN, n (%) | 91 (17) | 39 (24) | 52 (14) | < .01 |
| BM involvement, n (%) | 185 (47) | 82 (65) | 103 (38) | .001 |
| First-line treatment, n (%) | < .01 | |||
| R | 244 (45) | 72 (42) | 172 (46) | |
| BR | 110 (20) | 51 (29) | 59 (16) | |
| R-CHOP | 25 (5) | 6 (3) | 19 (5) | |
| R-CVP | 16 (3) | 8 (5) | 8 (2) | |
| Other systemic therapy | 20 (4) | 8 (5) | 12 (3) | |
| XRT | 19 (16) | 21 (12) | 70 (19) | |
| Surgery | 41 (7) | 7 (4) | 34 (9) | |
| Median follow-up (y) | 4.4 | 4.6 | 4.3 |
BM, bone marrow; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; R-CHOP, rituximab, cyclophosphamide, vincristine, and prednisone; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisone; ULN, upper limit of normal; XRT, radiation therapy.